Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate in Primary Biliary Cholangitis
NCT06365424Phase 3Recruiting
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Apr 2017
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of fenofibrate in primary biliary cholangitis (PBC) (2 arms), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoints: Treatment Emergent Adverse Events at 120 months and Percentage of patients with biochemical response at 120 months. Started Apr 2017; status: recruiting.
02
Drugs
fenofibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06365424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365424.